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OBJECTIVE—Phogrin and IA-2, autoantigens in insulin-depen-
dent diabetes, have been shown to be involved in insulin secretion
in pancreatic -cells; however, implications at a molecular level are
confusing from experiment to experiment. We analyzed biological
functions of phogrin in -cells by an RNA interference technique.
RESEARCH DESIGN AND METHODS—Adenovirus-mediated
expression of short hairpin RNA speciﬁc for phogrin (shPhogrin)
was conducted using cultured -cell lines and mouse islets. Both
glucose-stimulated insulin secretion and cell proliferation rate
were determined in the phogrin-knockdown cells. Furthermore,
protein expression was proﬁled in these cells. To see the binding
partner of phogrin in -cells, coimmunoprecipitation analysis
was carried out.
RESULTS—Adenoviral expression of shPhogrin efﬁciently de-
creased its endogenous expression in pancreatic -cells. Silenc-
ing of phogrin in -cells abrogated the glucose-mediated
mitogenic effect, which was accompanied by a reduction in the
level of insulin receptor substrate 2 (IRS2) protein, without any
changes in insulin secretion. Phogrin formed a complex with
insulin receptor at the plasma membrane, and their interaction
was promoted by high-glucose stimulation that in turn led to
stabilization of IRS2 protein. Corroboratively, phogrin knock-
down had no additional effect on the proliferation of -cell line
derived from the insulin receptor–knockout mouse.
CONCLUSIONS—Phogrin is involved in -cell growth via reg-
ulating stability of IRS2 protein by the molecular interaction with
insulin receptor. We propose that phogrin and IA-2 function as an
essential regulator of autocrine insulin action in pancreatic
-cells. Diabetes 58:682–692, 2009
G
lucose is a principle regulator of pancreatic
-cell survival and growth as well as insulin
secretion (1). It is a potent mitogen on pancreatic
-cells and regulates islet -cell mass through
their replication (2). Recent studies have suggested that
insulin secreted in response to elevated glucose exerts auto-
crine/paracrine effects, including promotion of insulin bio-
synthesis and proliferation of -cells (3,4). The importance of
insulin signaling in maintaining -cell mass was demon-
strated by targeted knockouts of the insulin receptor and
insulin receptor substrate 2 (IRS2) (5–8). Although insulin
receptor knockout had a restricted effect on -cell mass (7),
its mitogenic function on -cells was clearly shown by short
interfering RNA (siRNA)–based silencing of insulin receptor
in -cell–derived MIN6 cells (9,10). More recently, another
pathway was demonstrated showing that glucose metabo-
lism leads to increased -cell mass through the transcrip-
tional activation of IRS2 (11). Calcium/calmodulin-dependent
protein kinases and increased cAMP levels were suggested to
contribute to IRS2 expression, and this pathway has been
shown to be modulated by the incretin hormone glucagon-
like peptide 1 (GLP-1) (12,13). In both cases, IRS2 must be a
key mediator for glucose-responsive -cell growth (14).
Phogrin (IA-2) and IA-2 (ICA512) are integral glyco-
proteins localized to dense-core secretory granules in
various neuroendocrine cell types and have one inactive
protein-tyrosine phosphatase (PTP) domain in the cyto-
plasmic region (15–18). The targeted deletion of IA-2 or
phogrin or both in mice has resulted in mild impairment of
glucose-stimulated insulin secretion (GSIS) (19–21). How-
ever, it is uncertain whether the alteration is direct or
indirect and whether phogrin and IA-2 function at the
exocytotic machinery. To address these questions, cul-
tured -cell lines were used in further studies. Although
MIN6 stably overexpressing IA-2 showed a signiﬁcant
increment in both secretory granule number and insulin
secretion (22), transient overexpression of phogrin failed
to affect GSIS (23) or reduced it (24). Besides gene
transduction experiments, interaction of the IA-2 cytoplas-
mic tail with spectrin and/or syntrophin was found in
two-hybrid assay (25). Another function of IA-2 was also
proposed, involving the regulation of gene expression in
concert with signal transducer and activator of transcrip-
tion (STAT)5b (26,27). Furthermore, phogrin and IA-2 are
able to heterodimerize with other receptor-type PTPs,
such as RPTP, and prevent its activity in a transient
fashion (28). Unfortunately, it is still unknown whether all
of their interactions physiologically associate with a secre-
tion defect in knockout mice.
IA-2 family members are evolutionally conserved, and
the cytoplasmic region, including the PTP core domain, is
highly homologous, whereas the luminal region shows
lower homology between each of them (29). Although
phogrin and IA-2 have similar structures and functions,
their expression is regulated distinctly. IA-2 expression
increases in accordance with development in rodent tis-
sues (30–32). IA-2 expression in -cells is inﬂuenced by
glucose, insulin, cAMP-generating agents, and proinﬂam-
matory cytokines (32–34). In contrast, phogrin expression
is constant in the developmental stage of islets and is not
signiﬁcantly affected by glucose levels (32).
Because IA-2 expression is changeable and phogrin
expression is rather constitutive, we sought to deﬁne the
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682 DIABETES, VOL. 58, MARCH 2009role of phogrin using pancreatic -cells. Establishment of
stable cell lines expressing short hairpin RNA (shRNA) to
reduce phogrin levels prompted us to explore its novel
role in -cell growth. We found that phogrin knockdown
led to reduction of the IRS2 protein level and associated
growth retardation. Furthermore, we found that phogrin
binds to insulin receptor to modify IRS2 stability in -cells.
RESEARCH DESIGN AND METHODS
Anti-phogrin and anti–IA-2 antibodies were raised in rabbits against the
luminal region of phogrin and the luminal region of IA-2, respectively, and
were afﬁnity-puriﬁed. The guinea pig anti-insulin antibody and the anti–-
tubulin and anti–-actin mouse monoclonal antibodies were purchased from
Sigma. Anti-adaptin, anti–carboxypeptidase E (anti-CPE), anti–calcium-de-
pendent activator protein (anti-CAPS), anti-munc18, anti-dynamin, anti–clath-
rin heavy chain, anti–phosphatidylinositol 3-kinase (anti-PI3K), anti-Grb2, and
anti–extracellular signal–related kinase (anti-ERK) mouse monoclonal anti-
bodies and anti–insulin receptor -subunit (anti-IR) rabbit polyclonal anti-
bodies were from BD Biosciences. Anti-IRS1 and anti-STAT5 rabbit polyclonal
antibodies were from Cell Signaling. Anti-IRS2 rabbit polyclonal and anti-
epidermal growth factor receptor sheep polyclonal antibodies were from
Upstate Biotech. Anti–IGF-IR, anti-IR, anti-syntrophin, and anti–5-bromo-2-
deoxyuridine (anti-BrdU) mouse monoclonal antibodies were from Lab Vi-
sion, Chemicon, Afﬁnity Bioreagents, and Roche Diagnostics, respectively.
Anti–vesicle-associated membrane protein (anti-VAMP2) and anti–green ﬂu-
orescent protein (anti-GFP) rabbit polyclonal antibodies were from WAKO
chemicals and MBL, respectively.
DNA construction. The RNA polymerase III H1 gene promoter was cloned to
construct small interfering RNA expressing plasmid vector (pSUPER) accord-
ing to the reference (35). Oligonucleotides (64-base) corresponding to sense
target sequence, hairpin loop, and antisense target sequence were synthe-
sized, annealed together, and then ligated into pSUPER vector. The target
sense sequences were as follows: GGTCACCTTACAGAAGCTC (shPhogrin1)
(mouse Phogrin mRNA, 244–264), GCCACAACTCACACTACAA (shPhogrin2)
(mouse, 1,877–1,895; rat, 1,886–1,904), and GGATACATCCTCACAGGAA
(shPhogrin3) (mouse, 1,492–1,510; rat, 1,501–1,519) for phogrin, and GTCTG-
TATTCAGGATGGCT (shIA2) (mouse, 163–181; rat, 172–190) for IA-2.
Cell culture and transfection. MIN6 cells before passage 25 were cultured
in Dulbecco’s modiﬁed Eagle’s medium (DMEM) with 15% fetal bovine serum
(FBS) and 50 mol/l 2-mercaptoethanol. INS-1E cells were cultured in RPMI
1640 with 10% FBS, 10 mmol/l HEPES (pH 7.4), and 50 mol/l 2-mercapto-
ethanol. Transfections were performed with Lipofectamin 2000 reagent (In-
vitrogen, Carlsbad, CA). MIN6 cells were transfected with pcDNA3 vector plus
pSUPER plasmid, and stable clones were selected in the presence of G418
(36). Isolated colonies of the shPhogrin1-transfected cells were transferred to
new culture dishes for propagation (a total of 192 clones: 72 clones in the 1st
round, 120 clones in the 2nd round), but only two lines grew up to sufﬁcient
scales. Stable cell mixture transfected with empty pSUPER vector was
designated as MshV, and individual clones with reduced phogrin expression
were designated as MshP (MshP#33 and MshP#44). Insulin-producing cell
lines from -cell–speciﬁc insulin receptor–knockout (IRKO) mice were
established as described previously (37). Control cell lines (wild type) were
from littermates of IRKO mice. Mouse pancreatic islets were isolated and
cultured as described previously (38).
Adenovirus production. H1-RNA promoter and the inserted DNA were cut
by SmaI and HincII and then ligated into the promoterless cosmid pAdex
vector (pAxcw; TaKaRa Biomedicals, Otsv, Japan). A full-length mouse
phogrin cDNA was transferred to the pAdex vector (pAxCAwt). Viral produc-
tion and propagation was generated using HEK 293 cells. Positive clones were
selected by immunoﬂuorescence analysis of MIN6 cells with anti-phogrin
antibody. Puriﬁed adenoviruses were prepared by CsCl density gradient
centrifugation.
Insulin content and secretion. After 6 h from adenoviral infection, cells
(1.5  10
6 MIN6 cells/well, 2  10
6 INS-1 cells/well) were seeded into a
six-well plate for culture. The cells were extracted with acid ethanol for 15 h
at 4°C. After clariﬁcation of the extracts by centrifugation, the insulin
concentration was measured by radioimmunoassay (RIA) (Eiken Chemical,
Tokyo, Japan). The infected cells were preincubated in modiﬁed Krebs-Ringer
buffer (KRB) (39) containing 2 mmol/l glucose for 2 h and then incubated with
KRB supplemented with glucose at 25 mmol/l (for MIN6) or 16.8 mmol/l (for
INS-1) for 30 min. The cell number and the cellular protein content were
measured in all secretion experiments. Similar cell number was maintained
among all the samples. Thereby, normalized secreted insulin to either cell
number, total cellular proteins, or total insulin content did not show any
difference (data not shown).
Assessment of cell growth. After 6 h from adenoviral infection, MIN6 and
INS-1E cells were seeded into six-well plates at 0.5  10
6 and 1.5  10
6
cells/well, respectively. At an indicated time, cells were collected, and the cell
number was measured by a CyQUANT cell proliferation assay kit (Invitrogen).
The proliferative activity of infected cells was detected by BrdU incorpora-
tion. Cells were stained with 4,6-diamidino-2-phenylindole (DAPI) to calcu-
late the rate of BrdU-positive cells. DNA synthesis rates were measured by
[
3H]thymidine incorporation into islet cells. After 16 h from adenoviral
infection, mouse islets were cultured for 48 h. [
3H]thymidine was added at a
ﬁnal concentration of 1 mCi/ml to pools of 50 islets for an additional 24 h. The
proteins and DNA were precipitated with ice-cold 10% trichloroacetic acid and
solubilized in 0.3 N NaOH. Aliquots were counted in scintillation ﬂuid and
assayed for protein using the Bradford method.
Immunoprecipitation and immunoblotting analyses. Immunoprecipita-
tion and immunoblot analyses were performed as described previously (36).
For immunoprecipitation, MIN6 cells were extracted with lysis buffer (20
mmol/l Tris, pH 7.5, 150 mmol/l NaCl, 0.5% Nonidet P-40, 1 mmol/l EGTA, 0.5
mmol/l phenylmethylsulfonyl ﬂuoride, 10 g/ml aprotinin, 10 g/ml leupeptin,
and 10 g/ml pepstatin). Band density was measured by densitometry,
quantiﬁed using Gel plotting macros of NIH image 1.62 program, and normal-
ized to an indicated sample in the identical membrane.
Subcellular fractionation. Subcellular fractionation was performed as de-
scribed previously (39). Cells were suspended in buffer containing 250 mmol/l
sucrose, 20 mmol/l HEPES (pH 7.4), 2 mmol/l MgCl2, 2 mmol/l EGTA, and the
protease inhibitors. The cells were homogenized for 40 strokes by the tight-ﬁtting
dounce homogenizer. The total homogenate was centrifuged at 700 gfor 15 min
to pellet the nuclear and intact plasma membrane fraction. The resultant
supernatant was then centrifuged at 12,000  g for 20 min to separate the heavy
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FIG. 1. Expression levels of insulin signaling proteins are changed in
phogrin-silencing stable cells. A–D: Cell extracts were prepared from
MIN6 control cells, shVector-expressing stable cells (MshV), and two
distinct shPh1-expressing stable cells (clones 33 and 44). Each extract
normalized for total protein content was subjected to SDS-PAGE/
immunoblot analysis. Blots were probed with speciﬁc antibodies of
four categories: secretory granules-associated proteins (A), proteins
related to vesicle trafﬁcking (B), insulin signaling pathway proteins
(C), and others (D). E: Intensity of each band was quantiﬁed with the
densitometric imager, and the results from three independent experi-
ments are presented as fold increases  SE compared with MshV.
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DIABETES, VOL. 58, MARCH 2009 683organelle fraction, including the secretory granules, from the cytoplasmic mate-
rials. Fractionates were lysed, and equal proportions of each lysate were
subjected to immunoprecipitation and immunoblotting analysis.
Semiquantitative RT-PCR. Quantitative RT-PCR analysis was performed as
described previously (40). PCRs were performed using the following speciﬁc
primers: phogrin, 5-AGCCACGGTACCTTGTACAT-3 and 5-TTGTATGGCTC-
CAGCAACTG-3 (237 bp); IRS2, 5-TATCGCCATCGATGTGAGAGG-3 and
5-GTAGCGCTTCACTCTTTCACG-3 or 5-GCAGCACTTTACTCTTTCACC-3
(322 bp). Ampliﬁed signals stained with ethidium bromide were quantiﬁed by
ATTO cool saver system.
Statistical analysis. Results are given as the mean  SE, except where
indicated otherwise. Differences between groups were analyzed using Stu-
dent’s t test. P values 0.05 were considered statistically signiﬁcant.
RESULTS
Speciﬁc knockdown of Phogrin in -cell lines using
adenovirus-delivered shRNA. We developed a new an-
tibody (MatN2) with a high speciﬁcity to phogrin by
immunoblotting and immunostaining. To compare the
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FIG. 2. Effects of shRNA-expressing adenoviruses on GSIS and the proliferation of MIN6 cells. A: MIN6 cells were infected with adenoviruses
integrating shVector, shPh1, shPh2, shPh3, or shIA2 for 72 h. The expression levels of endogenous phogrin and IA-2 proteins were determined by
immunoblotting with speciﬁc antibodies for phogrin and IA-2. -Tubulin is a nontargeting control. B: MIN6 cells infected with Ad-shVec, shPh1,
shPh2, or shPh3 were immunostained with anti-phogrin antibody. C: MIN6 cells expressing shPh3 were ﬁxed at time points 24, 48, and 72 h. Cells
were then immunostained with anti-phogrin and anti-insulin antibodies. D: The infected cells were incubated for2hi nmodiﬁed KRB (2 mmol/l
glucose) before high-glucose stimulation. After stimulation for 30 min with 2 or 25 mmol/l glucose, culture media (left; secretion) and cells (right;
content) were collected and subjected to RIA for insulin. Data are given as means  SE of ﬁve independent experiments. E: Time course of MIN6
cell proliferation 24–96 h after infection with Ad-shVec, shPh1, shPh2, shPh3, or shIA2. Cell number was measured as indicated in RESEARCH DESIGN
AND METHODS. Phogrin-KD or IA2-KD cells grew more slowly than the shVec-infected cells (*P < 0.001, **P < 0.005). F: Cells infected by Ad-shVec
or shPh3 for 72 h were assayed for BrdU incorporation by immunoﬂuorescence analysis. Experiments were performed four times (n  12). (Please
see http://dx.doi.org/10.2337/db08-0970 for a high-quality digital representation of this ﬁgure.)
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684 DIABETES, VOL. 58, MARCH 2009phogrin expression in various endocrine cell lines, whole-
cell extracts were immunoblotted with MatN2. Phogrin
was highly expressed in two pancreatic -cell lines, MIN6
and HC9, whereas other cell lines, including rat INS-1,
expressed a lower level of phogrin (supplementary Fig.
S1A, available in an online appendix at http://dx.doi.org/
10.2337/db08-0970). We further produced an antibody spe-
ciﬁc to IA-2 and obtained a similar result (supplementary
Fig. S1B). However, we noted that IA-2 expression was
inconstant and changeable by cell culture conditions (data
not shown), which was consistent with the previous
observations (32–34). From these results, we chose MIN6
(high expression type) and INS-1 (moderate expression
type) for the knockdown study.
We produced three kinds of plasmids that direct the
synthesis of shRNAs targeted against the phogrin se-
quence (shPh1, shPh2, and shPh3). Transient expression
of each shRNA plasmid selectively reduced the production
of phogrin–enhanced GFP (EGFP) but not the control
EGFP (data not shown); however, endogeneous phogrin
was not sufﬁciently decreased in MIN6 cells because DNA
transfection is not efﬁcient by conventional transfection
methods. Thus, we initially established shRNA-expressing
stable cell lines, termed MshP#33 and MshP#44 (see
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FIG. 3. Effects of phogrin repression and overexpression on INS-1E cells. INS-1E cells were infected with adenoviruses integrating shVector or
shPh3 (A–D) or infected with adenoviruses expressing -galactosidase (LacZ) or phogrin (E–H). A and E: Cell extracts were prepared, and each
extract was subjected to immunoblotting with anti-phogrin antibodies. The infected cells were incubated in KRB with 2 or 16.8 mmol/l glucose
for 30 min. Secreted insulin (B and F) and intracellular total insulin (C and G) were measured by RIA and normalized to the total cell number.
Data are given as means  SE of at least four independent experiments. D and H: Cell growth was assessed as shown in Fig. 2E and F. Insets show
the BrdU incorporation rate at 72 h that is presented as the fold increases  SE compared with control (n  3, *P < 0.01). B and C: o, mock; ,
shVec; f, shPh3. F and G: o, mock; , LacZ; f, Phogrin.
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MatN2 conﬁrmed silencing of the endogenous phogrin
(Fig. 1A and E). Simultaneously, expression levels of
various proteins were also examined, including IA-2 (28),
-adaptin (36), syntrophin (25), STAT5 (27), and CAPS
(41), all of which have been reported to interact with IA-2
family proteins directly or indirectly. IA-2 protein levels in
MshP#33 and MshP#44 were less than those in control
cells; however, other secretory granule–resident proteins
and proteins involved in the exo/endocytosis were not
altered (Fig. 1A and B). Unexpectedly, we noted that
insulin signaling pathway-composing proteins were signif-
icantly affected: IRS1 and IRS2 were nearly undetectable,
and PI 3-kinase p85 and Grb2 were high (Fig. 1C and E).
Other proteins were unaffected in expression (Fig. 1D).
Because proliferation of MshP#33 and MshP#44 was
extremely slow, we found it difﬁcult to keep these cells
invariant throughout a number of experiments. Therefore,
we generated an adenovirus expression system to achieve
high efﬁciency shRNA expression. MIN6 cell lysates were
prepared at 72 h after the infection with adenoviruses
bearing shPh1, shPh2, shPh3, shIA2, or control vector. By
immunoblotting, endogenous phogrin was reduced by
6090% in shPhogrin-expressing cells, and Ad-shPh3 was
most effective (Fig. 2A). The knockdown effect was spe-
ciﬁc, because expression levels of IA-2 and -tubulin were
unaffected. Thus, reduction of IA-2 protein in MshP#33 and
MshP#44 cells may have resulted from long-term cell
cloning. Similarly, speciﬁc knockdown of IA-2 was accom-
plished by adenovirus shIA2 (Fig. 2A). Furthermore, the
silencing effects of adenoviral shPhogrin were veriﬁed by
immunostaining (Fig. 2B). Phogrin expression was re-
duced at 24 h after infection and most signals were
disappeared at 72 h in the shPh3-expressing MIN6 cells
(Fig. 2C). Insulin staining patterns were unchanged in
these phogrin-knockdown cells.
Phogrin regulates -cell growth. To assess the involve-
ment of phogrin in the -cell secretory function, GSIS and
total insulin content were determined in MIN6 cells.
Knockdown of phogrin or IA-2 did not result in any notable
effects on GSIS and insulin content (Fig. 2D). Similar
results were shown for INS-1E cells, which displayed no
signiﬁcant difference in GSIS and insulin content between
shPh3-expressing cells and control cells (Fig. 3A–C). Con-
versely, adenovirus-mediated phogrin overexpression did
not affect GSIS and insulin content in INS-1E cells (Fig.
3E–G). These observations indicate that insulin secretion
in the -cell lines remained unaltered when phogrin or IA-2
was attenuated or increased.
Next, we determined the cell proliferation rate by mea-
suring cell number. Silencing of phogrin or IA-2 reduced
MIN6 cell growth in a time-dependent manner (Fig. 2E).
No proapoptotic effects were observed at 72 h [5.8 (shVec),
6.7 (shPh1), 6.2 (shPh2), 5.7 (shPh3), and 6.8 (shIA2) % cell
death rates]. The proliferation rates of shPh1, shPh2,
shPh3, and shIA2-infected MIN6 cells, assessed at 72 h
after infection, were 84.0, 77.3, 72.5, and 69.9%, respec-
tively, compared with shVector-infected cells (P  0.001).
Moreover, the proliferation rate by BrdU incorporation per
DAPI-positive cells revealed a 30% decrease of BrdU
incorporation in shPh3-expressing cells (Fig. 2F). We
further conﬁrmed the similar inhibitory effect of phogrin
knockdown on the proliferation of INS-1E cells (Fig. 3D).
Consistently, adenoviral phogrin overexpression slightly
enhanced the proliferation of INS-1E cells (Fig. 3H). MIN6
cells were not affected by phogrin overexpression (data
not shown) perhaps because of a high expression of
endogenous protein. To test the effects of Ad-shPhogrin on
islet cell replication, mouse islets were incubated with
[methyl-
3H]thymidine. Phogrin knockdown caused a 36%
decrease in [
3H]thymidine incorporation into islet cell
DNA (Fig. 4A).
Because glucose is a potent regulator of -cell growth
and both MIN6 and INS-1 cells are glucose responsive, we
examined whether phogrin modulates the glucose-depen-
dent mitogenesis in MIN6 cells. MIN6 growth was abol-
ished by the phogrin knockdown in response to increasing
glucose concentrations from 11 to 25 mmol/l, although the
growth rate under the low-glucose culture (5 mmol/l)
was not inﬂuenced (Fig. 4B).
Phogrin regulates stability of IRS2 protein. Previous
reports suggested that insulin/IGF-I signaling (IIS) pro-
vides -cell mass (6). To address the function of phogrin,
we investigated IIS-associated activity and expression of
growth-related molecules. Phogrin knockdown in MIN6
cells resulted in a marked reduction in IRS2 protein level
(Fig. 5A), as seen in shPhogrin stable cell lines (Fig. 1).
Reduction of the IRS2 level was evident in phogrin-
knockdown cells 	48 h after infection, whereas such
reduction was undetected in shVector-infected cells even
at 72 h (Fig. 5A). IRS2 reduction was partially dependent
on the multiplicity of infection (MOI) number of adenovi-
ruses (Fig. 5B). In addition, insulin receptor was slightly
decreased in the cells having a higher degree of phogrin
knockdown (Fig. 5A and B). On the other hand, the
silencing of IA-2 protein caused a modest decrease in IRS2
protein but a marked reduction of an insulin receptor level
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686 DIABETES, VOL. 58, MARCH 2009(Fig. 5B). No signiﬁcant changes were noted in other
proteins, including IRS1 and other unrelated proteins,
suggesting the speciﬁc reduction of IRS2 and insulin
receptor. Similar reduction was also observed in INS-1E
cells (Fig. 5C) and mouse islets (Fig. 5D) in a time-
dependent manner. Furthermore, adenoviral phogrin over-
expression caused a partial recovery of IRS2 level in
shPhogrin stable cell lines (Fig. 5E), suggesting that pho-
grin speciﬁcally regulates IRS2 expression in -cells.
Recent studies have shown that glucose in the phys-
iological range (5–15 mmol/l) promotes IRS2 expression
at the transcriptional level (42); however, chronic expo-
sure to high glucose (	15 mmol/l) decreases IRS2
protein levels via proteasomal degradation in -cells
(43). We examined whether IRS2 protein is reduced
either by transcriptional regulation or by protein mod-
ulation in the phogrin-knockdown cells. Phogrin mRNA
was almost silenced at 24 h, and its decline was faster
than that of protein, as expected (Fig. 6A and B). In
contrast, IRS2 protein was decreased starting 48 h later,
whereas IRS2 mRNA level was barely affected even at
72 h (Fig. 6A and B). This suggests that phogrin regu-
lates the IRS2 expression at the protein level but not at
the mRNA level. Consistently, IRS2 reduction was com-
pletely blocked by the proteasomal inhibitors lactacys-
tin and MG-132 (Fig. 6C). Thus, IRS2 protein appears
unstable and is rapidly degraded by the proteasome in
the phogrin-knockdown cells. Inhibitors for autophagic/
lysosomal protein degradation had virtually no effect on
this event (Fig. 6C). Furthermore, IRS2 protein stability
was assessed by treatment of the translational inhibitor
cycloheximide (42). IRS2 protein levels in the phogrin-
knockdown cells decayed more rapidly than those in
control cells (Fig. 6D). Taken together, phogrin plays an
essential role in the stability of IRS2 protein but not in
its gene transcription.
Phogrin forms a complex with insulin receptor. To
elucidate the phogrin function, an in vitro binding assay
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extracts were incubated with bacterially expressed
GST-phogrin, and bound proteins were detected by
immunoblotting with anti–phospho-tyrosine antibodies.
Speciﬁc bands 95, 100, and 130 kDa were detected in
the membrane fraction to bind to GST-phogrin but not
to GST alone (supplementary Fig. S2, available in the
online appendix). The result indicates that tyrosine-
phosphorylated transmembrane proteins are candidates
as the phogrin-binding molecules. Coimmunoprecipita-
tion experiments using MIN6 cell lysates revealed that
both phogrin and IA2 immunoprecipitates contained a
signiﬁcant amount of insulin receptor -subunit (IR)
without its precursor (Fig. 7A; supplementary Fig. S3A,
available in the online appendix). IR was not detected
by the control antibodies. Furthermore, IR was barely
found in the phogrin immunoprecipitates from the pho-
grin-knockdown cells (Fig. S3B). These results suggest
that phogrin speciﬁcally interacts with the mature form
of insulin receptor. Unexpectedly, IRS2 and IGF-IR were
not coimmunoprecipitated with phogrin and IA-2 (Fig.
7A). When MIN6 cells were cultured in low-glucose
condition, their interaction was detected at a low level
by coimmunoprecipitation (Fig. 7B, 0-h point). Impor-
tantly, when cells were placed into the high-glucose
culture, IR content increased dramatically in the pho-
grin immunoprecipitates, although there was no change
in the phogrin and insulin receptor expression levels
(Fig. 7B). Notably, IRS2 apparently increased during the
high-glucose stimulation in MIN6 cells (Fig. 7B, right
panel), as previously shown for primary rat -cells (42).
Blockade of secretory granule exocytosis by diazoxide,
a potassium channel opener, completely prevented the
coimmunoprecipitation of insulin receptor (Fig. 7C).
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by immunoblotting. Accumulative data are presented as a percentage of the IRS2 protein levels at time 0 as means  SE (n  3).
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teraction of phogrin and insulin receptor presumably via
the translocation of phogrin into the plasma membrane.
To conﬁrm this idea, a conventional fractionation pro-
cedure was used. Under the low-glucose culture, pho-
grin and peripherally granule-associated Rab27a (39)
were mainly distributed in the secretory granule frac-
tion (Fig. 7D). The high-glucose stimulation induced
signiﬁcant redistributions of phogrin and Rab27a from
secretory granule to the plasma membrane fraction,
whereas the plasma membrane-associated insulin recep-
tor and syntaxin 1 remained in the plasma membrane.
Coimmunoprecipitation analyses using each fraction
revealed that molecular interaction between phogrin
and insulin receptor occurred at the plasma membrane
under the high-glucose condition (Fig. 7D, right bottom
panel). However, our results do not exclude a possibil-
ity that these proteins form a complex on secretory
granule that attached to the plasma membrane (44).
Finally, we used two -cell lines established from
control (wild-type) and IRKO mice for proliferation
assay. BrdU incorporation assay revealed that silencing
of phogrin failed to show the growth retardation of
IRKO -cells, whereas a 33% decrease in growth rate
was observed for wild-type -cells (Fig. 8A). Further-
more, IRS2 protein degradation caused by phogrin
knockdown was not observed in IRKO -cells (Fig. 8B
and C). This suggests that regulation of IRS2 stability
and -cell growth by phogrin depends on its interaction
with insulin receptor.
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Proliferation rates of phogrin-downregulated MIN6 stable
cells (Fig. 1) and phogrin-overexpressed stable cells (S.
Torii and T. Takeuchi, unpublished data) were reduced
and elevated, respectively. Thus, phogrin appeared to be a
positive regulator of -cell growth. Because studies using
stable cells seem inadequate for evaluation of primary
functions of phogrin, we generated adenoviruses express-
ing shRNA. As expected, silencing of phogrin by Ad-
shPhogrin caused a marked retardation of cell growth in
both cultured cell lines and mouse islets (Figs. 2–4).
However, GSIS stayed unaffected by phogrin or IA-2
knockdown (Figs. 2 and 3). Previous studies have shown
that the deletion of IA-2 or phogrin gene or in combination
in mice resulted in mild impairment of GSIS but did not
affect -cell mass (19–21). However, more recent studies
have suggested that islets from double knockout mice
failed to show any secretion defect (45), and -cell regen-
eration was reduced in partially pancreatectomized
ICA512 (IA-2) knockout mice (46). Therefore, it is possible
that the alteration in GSIS in knockout mice is indirect and
that -cell mass is recovered by compensatory function of
other genes. Our present results support the notion that
the primary function of phogrin is a regulation of -cell
growth but not of insulin secretion.
Glucose is a potent mitogen for -cells and regulates
various cellular dynamics, including insulin secretion and
nutritional metabolism (1). Although several signaling
molecules such as PKC have been thought to be a media-
tor for glucose-induced -cell growth (1), recent studies
have indicated a novel pathway in which the autocrine/
paracrine function of secreted insulin promotes -cell
proliferation (3,4). We demonstrated that -cell growth
retardation induced by phogrin knockdown was observed
under the high-glucose culture (Fig. 4B). Because phogrin
was found to form a complex with insulin receptor (Fig. 7)
and because cell growth retardation by phogrin knock-
down was not observed in insulin receptor–deﬁcient cells
(Fig. 8), insulin receptor is evidently a functional target of
phogrin. Phogrin localizes to insulin-containing secretory
granules and translocates to the plasma membrane when-
ever insulin exocytosis is induced (Fig. 7D) (36). Thus,
interaction of phogrin with insulin receptor is coordinately
coupled with the autocrine action of insulin. Their inter-
action was strikingly promoted by the high glucose-in-
duced insulin secretion (Fig. 7B–D). In other words,
phogrin regulates the glucose-induced -cell growth
through modulating the autocrine insulin signaling. Insulin
secretion was never inﬂuenced by overexpression or re-
pression of phogrin (Figs. 2 and 3), thereby, modulation of
autocrine effects by phogrin is not intervened by extracel-
lular insulin dosage.
Our subcellular fractionation experiments indicate that
phogrin interacts with insulin receptor on the plasma
membrane (Fig. 7D). However, EGFP-tagged phogrin in
MIN6 or PC12 cells did not spread to whole plasma
membrane under the evanescent microscopy observation
(44,47,48), suggesting that it remains on secretory granules
during exocytotic events. On the other hand, the experi-
mental result that phogrin antibody in culture medium
accessed to the cell surface phogrin protein in MIN6 cells
(49) suggests that phogrin positively reaches the cell
surface. Thus, the plasma membrane fraction in our assay
may contain the attached granules that had been con-
nected to the plasma membrane by lipid bilayers merger.
Because insulin receptor is reportedly distributed to the
methyl--cyclodextrin–sensitive microdomains of the
plasma membrane in HIT-T15 cells (50), it is possible that
phogrin and insulin receptor colocalize at uncharacterized
speciﬁc domains equivalent to the secretory granule tar-
geting/fusion sites.
Our data indicate that phogrin interacts with insulin
receptor and stabilizes IRS2 protein in -cells. This hy-
pothesis raises a question: What is the molecular mecha-
nism of this interaction? Because phogrin and IA-2 have an
inactive PTP domain in their cytoplasmic tail, it is possible
that they bind to insulin receptor directly. In fact, the
phogrin cytoplasmic fragment could bind to tyrosine-
phosphorylated 95- to 100-kDa proteins in vitro (supple-
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signaling through the tyrosine phosphorylation/dephos-
phorylation cycle. Insulin or IGF-I promotes degradation
of IRS2 through PI 3-kinase, Akt, and mTOR signaling in
adipocytes, hepatoma, and embryonic ﬁbroblast cells (51).
Also, chronic exposure (	8 h) to high glucose and/or IGF-I
induces proteasomal degradation of IRS2 in -cells (43).
These proposed signaling pathways may be mediated by
phogrin function for stabilization of IRS2.
Ablation of IRS2 in -cells led to a decrease in -cell
mass and an increase in islet apoptosis (5). In contrast,
IRS2 expression in mice prevented diabetes by promoting
-cell growth (52). Furthermore, IRS2 expression induced
by glucose, GLP-1, and other signaling proteins has been
shown to contribute to their regulatory functions for
proliferation, indicating that IRS2 is a master regulator of
-cell growth (14). Our data further indicate that IRS2
protein is stabilized under the control of phogrin and
insulin receptor interaction for its cell growth regulation.
This is because silencing of phogrin resulted in a marked
reduction of IRS2 without change in other protein levels.
Furthermore, adenoviral overexpression of phogrin
caused a partial recovery of IRS2 level in MshP#33 and
MshP#44 cells (Fig. 5E). Thus, phogrin functions as a
primary regulator of secreted insulin-mediated -cell
growth by stabilizing IRS2 protein.
To respond to hyperglycemia, -cells proliferate and
expand to compensate for increased insulin secretion
demand (14). The present observations suggested a novel
mechanism in which phogrin contributes to glucose-in-
duced proliferation of -cells via insulin receptor and
IRS2. Interestingly, insulin receptor and IRS2 mRNA levels
reportedly decreased in islets isolated from human type 2
diabetes (53). To prevent the decrease in insulin receptor
and IRS2 functions, we suggest that phogrin and IA-2 in
the -cells are potential therapeutic targets for treating
diabetes.
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